News|Articles|October 3, 2024
Neoadjuvant Sotigalimab Proves Efficacious in Rectal Cancer
Author(s)Ariana Pelosci
Fact checked by: Gina Mauro
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.
Advertisement
Advertisement
Sotigalimab demonstrated feasibility and an acceptable safety profile as neoadjuvant therapy for patients with rectal cancer, according to results from the phase 2 INNATE trial (NCT04130854) that were presented at the
Advertisement
Advertisement